Name

Company

Description

Phase III

Denosumab (AMG 162)

Amgen

Human monoclonal antibody that targets the receptor activator of nuclear factor kappa B ligand (RANKL) and inhibits bone destruction; trials testing denosumab alone and in combination with Zometa completed; under review by the FDA

Panobinostat (LBH589)

Novartis

Deacetylase (DAC) inhibitor; being evaluated in combination with other agents LEARN MORE

Perifosine (KRX-0401, D-21266)

Keryx

Oral anticancer agent that inhibits cell growth and promotes apoptosis; being evaluated alone and combination with other agents LEARN MORE

Zolinza® (vorinostat, SAHA [suberoylanilide hydroxamic acid])

Merck

Histone deacetylase (HDAC) inhibitor that has shown activity in relapsed and refractory myeloma LEARN MORE

Phase II

Afinitor® (everolimus, RAD001, Certican®)

Novartis

mTor inhibitor being evaluated in combination with other agents; known as Certican outside the US, where it is used in preventing transplant rejection

Aflibercept (VEGF Trap)

Regeneron/sanofi-aventis

Anti-angiogenic fusion protein that binds VEGF

Aplidin® (plitidepsin)

PharmaMar, SA

Marine-derived antitumor agent that induces rapid apoptosis LEARN MORE

Avastin®
(bevacizumab)

Genentech

Humanized antibody against the VEGF receptor FDA-approved for use in other cancers; being evaluated as part of several combination therapies

Bexxar® (iodine I 131 tositumomab)

GlaxoSmithKline

FDA-approved radiolabeled monoclonal antibody directed against CD20, a marker found on B cells and 20% to 25% of myeloma cells

Carfilzomib (PR-171)

Oxyx Pharmaceuticals

Proteasome inhibitor being evaluated alone, as part of combination therapy, and as maintenance therapy LEARN MORE

CNTO 328

Centocor Ortho Biotec

Anti-interleukin-6 monoclonal antibody being evaluated alone and in combination with Velcade and Velcade-MP LEARN MORE

Elotuzumab (HuLuc63; humanized anti-CS1 monoclonal antibody)

Facet Biotech/Bristol-Myers Squibb

Monoclonal antibody that binds to CS1, a cell surface protein that is highly expressed on myeloma cells; being evaluated alone and in combination with Velcade and with Revlimid-Dex LEARN MORE

IPH2101

Innate Pharma

Monoclonal antibody that enhances killing of myeloma cells by natural killer (NK) cells

Istodax® (romidepsin)

Celgene

Histone deacetylase (HDAC) inhibitor approved for use in a specific type of lymphoma; being evaluated in combination with Velcade

Nexavar® (sorafenib)

Bayer/Onyx Pharmaceuticals

Multi-kinase inhibitor FDA-approved for use in renal cell carcinoma that inhibits cell growth and angiogenesis; being evaluated alone and in combination with other agents

PD 0332991

Pfizer

Kinase inhibitor being evaluated in combination with Velcade and dexamethasone

Pomalidomide (CC-4047)

Celgene Corporation

Type of IMiD™ (immunomodulatory drug) being evaluated alone and in combination with dexamethasone LEARN MORE

Rituxan® (rituximab)

Genentech/Biogen Idec

Monoclonal antibody FDA-approved for use in non-Hodgkin lymphoma that targets the CD20 marker found on B cells and 20% to 35% of myeloma cells

SRT501

Sirtris, a GlaxoSmithKline company

A formulation of resveratrol (compound found in grapes and red wine) being evaluated alone and in combination with Velcade

TKI258

Novartis

Oral tyrosine kinase inhibitor that displays antitumor activity and inhibits angiogenesis

Romidepsin (depsipeptide, FK228, FR901228)

Gloucester Pharmaceuticals/Janssen-Cilag Ltd.

Histone deacetylase (HDAC) inhibitor being evaluated in combination with Velcade

Sprycel® (dasatinib)

Bristol-Myers Squibb

Kinase inhibitor FDA-approved for use in chronic myelogenous leukemia; being evaluated in combination with Velcade or Revlimid-dex

Torisel™ (temsirolimus, CCI-779)

Wyeth

mTOR inhibitor FDA-approved for use in renal cell carcinoma; being evaluated alone and in combination with other agents

Trisenox® (arsenic
trioxide, ATO)

Cephalon

Anticancer drug FDA-approved for use in acute promyelocytic leukemia

Vidaza® (azacitidine)

Celgene

Cytotoxic drug FDA-approved for the treatment of myelodysplastic syndromes (MDS)

Zarnestra™ (R115777, tipifarnib,FTI)

Ortho Biotech Oncology Research & Development

Farnesyl transferase inhibitor; activity seen in combination with Velcade in a phase I trial

Phase I

Anti-KIR (1-7F9)

Novo Nordisk

Monoclonal antibody that activates the body's natural killer cells to kill tumor cells

ARRY-520

Array BioPharma

Agent shown to be effective alone and in combination with Velcade or Revlimid in a mouse model of myeloma

AUY922

Novartis

Heat shock protein (HSP90) inhibitor being tested alone and in combination with other Velcade, with or without dexamethasone

BI-505

BioInvent International AB

Monoclonal antibody directed against ICAM-1, a protein that enables immune cells to migrate from the blood into tissues

BKT140

Biokine Therapeutics

Novel agent that causes myeloma cell death

BMS-833923

Bristol-Myers Squibb

Oral anticancer agent being evaluated alone and in combination with Revlimid-dex or Velcade

BT062

Biotest AG

Anti-CD138 monoclonal antibody/cytotoxic agent compound that has demonstrated activity in early testing

CEP-18770

Cephalon

Proteasome inhibitor

Dacetuzumab (SGN40)

Seattle Genetics

Monoclonal antibody directed against CD40 that has shown activity in combination with Revlimid-dex; also being evaluated in combination with Velcade

GRN163L

Geron Corp.

Telomerase inhibitor that has been shown in vitro to induce apoptosis and inhibit myeloma cell growth; being evaluated alone and in combination with Velcade

HCD122

Novartis

Anti-CD40 monoclonal antibody

HuMax-CD38

Genmab

Human monoclonal antibody that targets the CD38 molecule, which is highly expressed on the surface of myeloma cells

Imetelstat (GRN163L)

Geron Corp.

Telomerase inhibitor that has been shown in vitro to induce apoptosis and inhibit myeloma cell growth; being evaluated alone and in combination with Velcade

IMGN901 (huN901-DM1, BB-10901)

Immunogen

Monoclonal antibody directed against the CD56 marker found on myeloma cells, coupled with a cancer drug; activity shown in heavily pretreated myeloma

LY2127399

Lilly

Antibody directed against a protein that activates B cells being tested in combination with Velcade

Milatuzumab (hLL1, IMMU-110)

Immunomedics

Humanized monoclonal antibody directed against the CD74 protein found on B cells and myeloma cells

MLN4924

Millennium: The Takeda Oncology Company

Novel agent

MLN8237

Millennium: The Takeda Oncology Company

Novel agent (Aurora A kinase inhibitor) being evaluated in combination with Velcade

MLN9708

Millennium: The Takeda Oncology Company

Oral second-generation proteasome inhibitor

Noscapine (CB3304)

Johnson & Johnson

Cough suppressant that inhibits the growth of several types of cancer cells

NPI-0052

Nereus

Novel proteasome inhibitor that has shown promising early safety data

Oncolytic measles virus (MV-NIS)

Mayo Clinic

Genetically engineered measles virus being administered with or without cyclophosphamide

Salinosporamide A (NPI-0052)

Nereus Pharmaceuticals

Novel marine derived proteasome inhibitor active against myeloma cells that are resistant to Velcade

SGN40

Seattle
Genetics

Monoclonal antibody directed against CD40 being evaluated in combination with Revlimid-dex or Velcade

Treanda®,
(bendamustine
hydrochloride; known as Ribomustin® in Germany)

Cephalon Oncology

Alkylating agent FDA-approved for use in treating leukemia and approved in Germany for use in myeloma; being evaluated as part of various combination therapies for use in newly diagnosed and relapsed and/or refractory disease

Zemplar™ (paricalcitol)

Abbott

Activated vitamin D therapy being evaluated in combination with Zometa

Zevalin® (yttrium Y 90 ibritumomab tiuxetan)

Cell Therapeutics, Inc.

Radiolabeled monoclonal antibody FDA-approved for use in combination with Rituxan (rituximab) for the B-cell non-Hodgkin’s lymphoma; the combination is being evaluated prior to high-dose melphalan and stem cell transplant